In the past week, CGON stock has gone up by 6.43%, with a monthly decline of -21.86% and a quarterly plunge of -30.02%. The volatility ratio for the week is 6.15%, and the volatility levels for the last 30 days are 9.64% for Cg Oncology Inc The simple moving average for the last 20 days is 5.12% for CGON stock, with a simple moving average of -31.63% for the last 200 days.
Is It Worth Investing in Cg Oncology Inc (NASDAQ: CGON) Right Now?
Additionally, the 36-month beta value for CGON is 1.41. There are mixed opinions on the stock, with 5 analysts rating it as a “buy,” 3 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
The public float for CGON is 46.04M and currently, short sellers hold a 17.48% ratio of that float. The average trading volume of CGON on April 25, 2025 was 848.40K shares.
CGON) stock’s latest price update
The stock of Cg Oncology Inc (NASDAQ: CGON) has increased by 3.81 when compared to last closing price of 20.73. Despite this, the company has experienced a 6.43% gain in its stock price over the last five trading sessions. seekingalpha.com reported 2025-04-02 that CG Oncology, Inc.’s lead asset, cretostimogene grenadenorepvec, shows promising efficacy in bladder cancer with competitive complete response rates in clinical trials. Recent data updates reveal a 74.5% CR rate in the BOND-003 trial and a 41.2% CR rate in a phase 1 trial for MIBC. A basic DCF valuation estimates CGON’s enterprise value at $5.3bn, suggesting a price target of $69, about 3x the current price.
Analysts’ Opinion of CGON
Many brokerage firms have already submitted their reports for CGON stocks, with Scotiabank repeating the rating for CGON by listing it as a “Sector Perform.” The predicted price for CGON in the upcoming period, according to Scotiabank is $23 based on the research report published on April 16, 2025 of the current year 2025.
UBS gave a rating of “Buy” to CGON, setting the target price at $60 in the report published on October 24th of the previous year.
CGON Trading at -11.56% from the 50-Day Moving Average
After a stumble in the market that brought CGON to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -54.20% of loss for the given period.
Volatility was left at 9.64%, however, over the last 30 days, the volatility rate increased by 6.15%, as shares sank -18.91% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -21.80% lower at present.
During the last 5 trading sessions, CGON rose by +6.43%, which changed the moving average for the period of 200-days by -32.83% in comparison to the 20-day moving average, which settled at $20.47. In addition, Cg Oncology Inc saw -24.97% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CGON starting from POST LEONARD E, who sale 1,000 shares at the price of $28.00 back on Mar 17 ’25. After this action, POST LEONARD E now owns 0 shares of Cg Oncology Inc, valued at $28,000 using the latest closing price.
LEONARD E POST, the Director of Cg Oncology Inc, proposed sale 4,000 shares at $27.80 during a trade that took place back on Mar 17 ’25, which means that LEONARD E POST is holding shares at $111,200 based on the most recent closing price.
Stock Fundamentals for CGON
Current profitability levels for the company are sitting at:
- -100.67 for the present operating margin
- 0.99 for the gross margin
The net margin for Cg Oncology Inc stands at -77.29. The total capital return value is set at -0.16. Equity return is now at value -19.18, with -18.45 for asset returns.
Based on Cg Oncology Inc (CGON), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -330.73.
Currently, EBITDA for the company is -114.67 million with net debt to EBITDA at 2.24. When we switch over and look at the enterprise to sales, we see a ratio of 1226.11. The receivables turnover for the company is 1.46for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 35.30.
Conclusion
In conclusion, Cg Oncology Inc (CGON) has seen bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
